2022-500398-15-00已完成1 期
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants.
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2022年10月3日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 64
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin2025-521921-34-00Genentech Inc.32
招募中
1 期
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control2024-519277-18-00F. Hoffmann-La Roche AG40
招募中
2 期
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)Venous Thromboembolism2023-508603-21-00Regeneron Pharmaceuticals Inc.93
招募中
1 期
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.2023-505185-28-00F. Hoffmann-La Roche AG52
已完成
1 期
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.2023-506564-14-00Celgene International II S.a.r.l.112